Fragment-based QSAR: perspectives in drug design

被引:0
|
作者
Lívia B. Salum
Adriano D. Andricopulo
机构
[1] Universidade de São Paulo,Laboratório de Química Medicinal e Computacional, Centro de Biotecnologia Molecular Estrutural, Instituto de Física de São Carlos
来源
Molecular Diversity | 2009年 / 13卷
关键词
Drug design; SAR; QSAR; Fragment-based; Pharmacodynamics; Pharmacokinetics;
D O I
暂无
中图分类号
学科分类号
摘要
Drug design is a process driven by innovation and technological breakthroughs involving a combination of advanced experimental and computational methods. A broad variety of medicinal chemistry approaches can be used for the identification of hits, generation of leads, as well as to accelerate the optimization of leads into drug candidates. Quantitative structure–activity relationship (QSAR) methods are among the most important strategies that can be applied for the successful design of small molecule modulators having clinical utility. Hologram QSAR (HQSAR) is a modern 2D fragment-based QSAR method that employs specialized molecular fingerprints. HQSAR can be applied to large data sets of compounds, as well as traditional-size sets, being a versatile tool in drug design. The HQSAR approach has evolved from a classical use in the generation of standard QSAR models for data correlation and prediction into advanced drug design tools for virtual screening and pharmacokinetic property prediction. This paper provides a brief perspective on the evolution and current status of HQSAR, highlighting present challenges and new opportunities in drug design.
引用
收藏
页码:277 / 285
页数:8
相关论文
共 50 条
  • [1] Fragment-based QSAR: perspectives in drug design
    Salum, Livia B.
    Andricopulo, Adriano D.
    [J]. MOLECULAR DIVERSITY, 2009, 13 (03) : 277 - 285
  • [2] Fragment-based QSAR strategies in drug design
    Salum, Livia B.
    Andricopulo, Adriano D.
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2010, 5 (05) : 405 - 412
  • [3] Fragment-Based Quantitative Structure-Activity Relationship (FB-QSAR) for Fragment-Based Drug Design
    Du, Qi-Shi
    Huang, Ri-Bo
    Wei, Yu-Tuo
    Pang, Zong-Wen
    Du, Li-Qin
    Chou, Kuo-Chen
    [J]. JOURNAL OF COMPUTATIONAL CHEMISTRY, 2009, 30 (02) : 295 - 304
  • [4] In silico fragment-based drug design
    Konteatis, Zenon D.
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2010, 5 (11) : 1047 - 1065
  • [5] In Silico Approaches for Fragment-based Drug Design
    Takahashi, Osamu
    Masuda, Yoshiaki
    Muroya, Ayumu
    Furuya, Toshio
    [J]. YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2010, 130 (03): : 349 - 354
  • [6] The ways and means of fragment-based drug design
    Doak, Bradley C.
    Norton, Raymond S.
    Scanlon, Martin J.
    [J]. PHARMACOLOGY & THERAPEUTICS, 2016, 167 : 28 - 37
  • [7] Applications of ?linkers? in fragment-based drug design
    Wu, Xin
    Zhang, Yuan
    Liu, Songbin
    Liu, Chang
    Tang, Guotao
    Cao, Xuan
    Lei, Xiaoyong
    Peng, Junmei
    [J]. BIOORGANIC CHEMISTRY, 2022, 127
  • [8] Puzzling through fragment-based drug design
    Hajduk, Philip J.
    [J]. NATURE CHEMICAL BIOLOGY, 2006, 2 (12) : 658 - 659
  • [9] Comptational methods in fragment-based drug design
    Williams, Chris
    Leonard, Joseph M.
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
  • [10] Puzzling through fragment-based drug design
    Philip J Hajduk
    [J]. Nature Chemical Biology, 2006, 2 : 658 - 659